Actively Recruiting
TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus
Led by University of California, San Diego · Updated on 2026-02-24
28
Participants Needed
1
Research Sites
200 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase 2, randomized, open-label, single-center study that will assess the efficacy of TriCalm Hydrogel®, a topical gel containing strontium, for treating pruritus related to immune checkpoint inhibitors (ICIs).
CONDITIONS
Official Title
TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older
- Receiving immune checkpoint inhibitors for hematologic or oncologic cancers at UC San Diego Moores Cancer Center
- Developed grade 1-3 itching after at least one dose of immune checkpoint inhibitor
- Allowed preexisting oral antihistamines or GABA analogs if started more than 7 days before study entry
You will not qualify if you...
- Diagnosis of primary skin disorders causing itching (e.g., atopic dermatitis, psoriasis)
- Started any new oral or topical antipruritic medication or systemic corticosteroids within 7 days before study entry
- Presence of open wounds on the skin
- Itching located on the face
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California San Diego
La Jolla, California, United States, 92037
Actively Recruiting
Research Team
K
Karen M Yun, MD
CONTACT
L
Lung Research Team
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here